Last reviewed · How we verify
Humanalbumin 5%
Humanalbumin 5% is a human serum albumin solution that acts as a plasma volume expander and carrier protein to maintain oncotic pressure and transport endogenous substances.
Humanalbumin 5% is a human serum albumin solution that acts as a plasma volume expander and carrier protein to maintain oncotic pressure and transport endogenous substances. Used for Hypovolemia and shock management, Plasma volume expansion in critical care settings, Albumin replacement in hypoalbuminemia.
At a glance
| Generic name | Humanalbumin 5% |
|---|---|
| Also known as | Humanalbumin 5% Baxter |
| Sponsor | Medical University of Vienna |
| Drug class | Plasma volume expander; blood product derivative |
| Modality | Small molecule |
| Therapeutic area | Critical Care; Hematology; Trauma |
| Phase | FDA-approved |
Mechanism of action
Human serum albumin is a naturally occurring protein that maintains colloid osmotic pressure in the blood, preventing fluid shift from the intravascular space into tissues. It also serves as a carrier protein for various endogenous and exogenous substances, including hormones, fatty acids, and drugs. The 5% concentration provides moderate oncotic support for fluid resuscitation and maintenance of hemodynamic stability.
Approved indications
- Hypovolemia and shock management
- Plasma volume expansion in critical care settings
- Albumin replacement in hypoalbuminemia
Common side effects
- Fever
- Chills
- Nausea
- Hypersensitivity reactions
- Hypervolemia (with excessive administration)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Humanalbumin 5% CI brief — competitive landscape report
- Humanalbumin 5% updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI